Clovis kicks off PhII for rucaparib; Aerie nets $68.4M in IPO;

@FierceBiotech: Parexel's stock plunges despite spikes in revenue, profit. Report from FierceCRO | Follow @FierceBiotech

@JohnCFierce: Feds launch probe of AstraZeneca's controversial late-stage Brilinta study. Article | Follow @JohnCFierce

@DamianFierce: Do-it-all CRO inVentiv is buying Catalina Health to boost its patient adherence business. News | Follow @DamianFierce

@EmilyMFierce: New survey details impact of federal cuts, sequestration on scientific research. FierceBiotech Research story | Follow @EmilyMFierce

> Clovis Oncology ($CLVS) has enrolled its first patients in a Phase II study of ovarian cancer hopeful rucaparib, using gene sequencing to identify ideal candidates for the PARP inhibitor. More

> CytRx ($CYTR) posted positive results from its ongoing Phase IIb study of aldoxorubicin as a first-line treatment for advanced soft tissue sarcomas. News

> With over-allotments covered, Aerie Pharmaceuticals ($AERI) netted $68.4 million from its IPO this month, the company said. Item

Medical Device News

@FierceMedDev: Veracyte goes public, raises $65M and gains on Day 1. Article | Follow @FierceMedDev

@MarkHFierce: Carlos Slim backs more genomics and Dx work at the Broad Institute, and elsewhere, with a new infusion of $74M. FierceDiagnostics story | Follow @MarkHFierce

@MichaelGFierce:  | Follow @MichaelGFierce

> HeartMate pump propels Thoratec revenue. More

> Elixir's dissolving stent aces 12-month study as Abbott duel looms. Story

> Abbott, Cordis-backed study challenges stent options for coronary bifurcation lesions. Item

Pharma News

@FiercePharma: Biggest report yesterday: Top 10 Drug Patent Losses of 2014. Feature | Follow @FiercePharma

@CarlyHFierce:  CEO Jeremy Levin steps down amid board squabble. Top story yesterday via FiercePharma | Follow @CarlyHFierce

> Who wants to step into Teva's CEO hot seat? Story

> Novo Nordisk recruiting 400 U.S. sales reps as growth decelerates. Article

Pharma Manufacturing News

@EricPFierce: Manufacturing, sanitation issues at Sanofi's Toronto vaccine plant has been a problem for some time now. Story | Follow @EricPFierce

> Foreign cancer-drug dealer gets prison. More

> Space issues lead GSK to close NJ facility, shift production. Report

> DSM opens Australia biologics plant. Story

> India renews duty on Chinese paracetamol. Article

Vaccines News

> Sanofi makes case for Fluzone superior clinical benefit label. News

> GSK, Sanofi join Gates Foundation vaccine R&D initiative. Report

> Vaccines a rare bright spot in Merck's gloomy financials. More

> ACIP recommendation gives Novartis a new growth opportunity. Story

> Dendreon reportedly seeking buyer for struggling business. Article

Suggested Articles

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Gilead names Dickinson to CFO role; MedImmune CSO Herbst nabs CSO job at Pyxis; Checkmate picks up Wooldridge for CMO.

The readout is a key moment in the history of the drug and Mirati, shares in which have soared in the updraft created by data on Amgen’s rival asset.